Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 10,180,000 shares, a growth of 10.5% from the May 31st total of 9,210,000 shares. Based on an average trading volume of 1,280,000 shares, the days-to-cover ratio is presently 8.0 days.
Hedge Funds Weigh In On Aurinia Pharmaceuticals
A number of large investors have recently modified their holdings of AUPH. Cetera Advisors LLC increased its stake in Aurinia Pharmaceuticals by 18.9% during the 1st quarter. Cetera Advisors LLC now owns 60,139 shares of the biotechnology company’s stock valued at $301,000 after purchasing an additional 9,547 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Aurinia Pharmaceuticals during the first quarter valued at about $78,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Aurinia Pharmaceuticals by 15.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 38,952 shares of the biotechnology company’s stock worth $196,000 after acquiring an additional 5,079 shares during the last quarter. Patten & Patten Inc. TN acquired a new stake in shares of Aurinia Pharmaceuticals in the 1st quarter worth about $386,000. Finally, Vanguard Group Inc. lifted its position in Aurinia Pharmaceuticals by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 1,531,617 shares of the biotechnology company’s stock valued at $7,673,000 after acquiring an additional 21,119 shares in the last quarter. 36.83% of the stock is currently owned by institutional investors.
Aurinia Pharmaceuticals Price Performance
Shares of NASDAQ AUPH opened at $5.71 on Monday. The firm has a market capitalization of $814.59 million, a P/E ratio of -13.28 and a beta of 1.44. The firm’s 50-day moving average price is $5.33 and its 200-day moving average price is $6.30. The company has a current ratio of 5.60, a quick ratio of 5.05 and a debt-to-equity ratio of 0.19. Aurinia Pharmaceuticals has a 1-year low of $4.71 and a 1-year high of $12.43.
Analyst Upgrades and Downgrades
Separately, StockNews.com raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Aurinia Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $10.00.
Check Out Our Latest Stock Report on AUPH
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Further Reading
- Five stocks we like better than Aurinia Pharmaceuticals
- Do ETFs Pay Dividends? What You Need to Know
- 3 Stocks Upgraded by Analysts: Home Depot, U.S. Steel, Alcoa
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- NVIDIA and TSM Stock: Is Semiconductor Sector Momentum Slowing?
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Palo Alto Networks Stock Gains AI-Powered Cybersecurity Solutions
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.